Multikine
Navigation Links
Multikine in Medical News
CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
...oduct in the country. CEL-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. Launch of cold 4 d...rehensive immunotherapy that targets newly diagnosed head and neck cancer. multikine is cleared by the FDA and the Canadian regulators for a global Phase III cl......-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. ...or registering the product in the Territory. Once multikine has been approved, CEL-SCI will be responsible for...reement is consistent with our strategy to license multikine in the emerging markets to share the expenses of b...
CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
...gave clearance for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de......cess, eliminating a key risk of the pivotal trial. multikine represents a completely novel medicine with blockb...reak the annual billion-dollar sales barrier'. Our multikine was one of the 10 medicines named." The article ...of the highlights include: -- FDA clearance of multikine for Phase III clinical trial in head and neck ...
CEL-SCI Corporation Releases Letter to Shareholders
... Company highlights of 2007: -- FDA clearance of multikine for Phase III clinical trial in head and neck cancer -- Raised U.S. $15 million -- multikine granted Orphan drug designation in U.S. -- Started build-out of manufacturing facility for multikine to support upcoming Phase III study and commer...CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin... a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head an...New Help for Head and Neck Cancer
...oost the immune system. Patients received the multikine injections for 10 days. Two patients had a complet...e seen with the therapy. The authors conclude multikine injections may be valuable in the treatment of hea...fine the best dosage and mode of administration of multikine in patients with head and neck cancer.” ...Multikine in Medical Technology
VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Cent...
VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the...
VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the...
CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
Biomedical Real Estate Group Backs Construction of Facility VIENNA, Va., Aug. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM ) announced today that it has entered into an agreement with a biomedical real estate group under which CEL-SCI acquires long term use of a dedicated...CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
Partner to Make Direct Investment in CEL-SCI VIENNA, Va., Nov. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has expanded its exclusive licensing agreement for Multikine(R) with Orient Europharma Co., Ltd. ("Orient Europharma"), a leading pharmaceutica...CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery VIENNA, Va., May 21, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announced today that its cancer drug Multikine(R) was shown to significantly increase long term overall survival in a Phase II study of head and neck cancer pat...CEL-SCI Corporation Releases Letter to Shareholders
...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...n the go-ahead for a Phase III clinical trial with multikine and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...CEL-SCI Corporation Releases Letter to Shareholders
... Teva will participate in and pay for part of the multikine Phase III trial. We extended our multikine licensing agreement with Orient EuroPharma of Ta... our Phase III trial. multikine was named one of 10 future blockbuster drugs by M...CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
... 8, 2008. This dedicated facility will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ... our product development." CEL-SCI is developing multikine for approval as a first line indication in head an...Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head ...CEL-SCI Corporation Reports First Quarter Financial Results
...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...is currently building a manufacturing facility for multikine close to Baltimore, MD. Upon completion of the fac...Multikine in Biological News
...t cold temperatures.
"We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...
Multikine in Biological Technology
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...CEL-SCI Corporation Releases Letter to Shareholders
...facturing. This facility was built to manufacture multikine for the Phase III trial and sale thereafter. Due ...ng anywhere else. This means that we can fill our multikine into vials in a completely sterile manner not only... pharmaceutical/biotechnology drug industry. multikine cancer therapy: We believe that the most cri...CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
...eration of our H1N1 swine flu work and the validation of our manufacturing facility for contract manufacturing services and to produce our cancer drug multikine for the planned Phase III clinical trial." The securities described above are being offered by CEL-SCI Corporation pursuant to a registration sta......ntigen specificity with immune response modulation. CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is multikine which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. When used in this...
...t cold temperatures. "We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...
CEL-SCI Corporation Announces 2008 Financial Results
... fiscal 2008 in preparing for our pivotal trial of multikine for head and neck cancer. Expenditures for 2009 ar...sh expenditures. In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to...CEL-SCI Corporation Releases Letter to Shareholders
...people had expected and clearly make our non-toxic multikine cancer product even more important to develop. Se... Organization (BIO) which would help CEL-SCI bring multikine to market faster. Last, what percentage of people...er I also want to review the general status of our multikine cancer drug: 1. In the last few months we...Updated Pictures of CEL-SCI Manufacturing Facility Available Online
...ng and FDA cleared Phase III clinical trial, as well as commercial sale, of multikine as a first line indication in treatment naive head and neck cancer patients...h other potential partners are ongoing. In Phase II clinical trials multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% ...CEL-SCI Takes Delivery of New Manufacturing Facility
...y, located in the Baltimore area, will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ...n line for manufacturing." CEL-SCI is developing multikine for approval as a first line indication in head an...CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
...g facility and starting the Phase III study of our multikine cancer drug. Some additional funds were spent on o..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...Other TagsMagicSyphilisSyphilisCoatedCoatedCoatedColourImmunizationFungalFungalFungalCholeraOther Contentsaffinityaffinityaffinityaffinityaffinityaffinityaffinityaffinityalbuminalbuminalbuminalbuminalbuminalbuminalbuminalbuminalbuminfrequencyfrequencyfrequencyfrequencyfrequencyfrequencyfrequencyfrequencyfrequencyallelealleleallelealleleallelealphaalphaalphaalphaalphaalphaalphaalphaalternativealternativealternativealternativealternativealternativealternativealternativealternativeamineamineamine
MinusculeVolcanicMagicSyphilisCoatedColourCryoablationImmunizationOpeningFungalGroundbreakingUnicellularCSIROCholera
(Date:11/26/2009)...al rollercoaster, study finds , , THURSD...actor meets the jubilant sports fan. , A new st...ho root for the winning team -- enjoy the greatest...d victory was in doubt, producing feelings of worr...iving weekend as you,re glued to the TV set, watch...
(Date:11/26/2009)..., P.A. is offering free nationwide confidential co...rol pills who have suffered a Deep Vein Thrombosis...r other related cardiac issues or had their Gallbl...56-6405 or go to the firm’s website at http...valuation form. , (PRWEB)...
(Date:11/25/2009)...leMedicalInc.,aleadingmanufacturerofbreastMRIcoils...wleadingedgeclinicalapplicationsonitsAegis(TM)medi...SocietyofNorthAmerica(RSNA)annualmeetinginChicago,...leveragetheuniquehighqualityimagesgeneratedbySenti...eimagingmodalitiesformulti-parametricassessment. ,...
(Date:11/25/2009)...s,andPressJoinEfforttoEducate ,, MEMPHIS,Tenn....nalBipolarFoundationandtheMedicAlertFoundationrece...ram,whichisnowbeingwidelyacceptedasapreventiveheal...ipolarFoundationreceivedaproclamationofendorsement...ouisianaMitchLandrieu.TheNationalBipolarFoundation...
(Date:11/25/2009)... draw definite conclusions, experts say, , ...abetic patients with blocked coronary arteries, th... year whether patients undergo bypass surgery or a...rt. , Bypass surgery has been the standard trea...isease. However, less invasive approaches such as ...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Stenting May Equal Bypass for Diabetic Heart Patients 2Health News:Stenting May Equal Bypass for Diabetic Heart Patients 3[0] Watching the Nail-Biting Big Game Hurts So Good[0] Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills[1] Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology[0] First Time-Door is Open for Family Discussion of Bipolar Disorder[1] Stenting May Equal Bypass for Diabetic Heart Patients
(Date:11/23/2009)...evidence that the "synergistic" effect of early-li...ion and indoor endotoxin causes more harm to devel... , Environmental health scientists at the Unive...shown that children exposed to both high levels of...ring early life are six times more likely to exper...
(Date:11/23/2009)...ion Society says that western lowland gorillas liv...of the "mother lode" of more than 125,000 gorillas...eatened by growing humans activity in the region. ...orests adjacent to the southwest border of Lac Tl ...hat high densities of the great apes still exist i...
(Date:11/23/2009)...vailable for the H1N1 virus has been sent to vacci...cination marks the first time vaccine has been sen..., Iowa State University,s Hank Harris, professor...mer and has been shipping preventive doses to swin...al weeks., The latest vaccines were shipped to a...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Netech Corporation Announces the Release of IPA 2000 Infusion Pump Analyzer for Fast and Accurate Testing of All Infusion Pumps 14891 1Netech Corporation Announces the Release of IPA 2000 Infusion Pump Analyzer for Fast and Accurate Testing of All Infusion Pumps 14891 2WellGen Recognized as Nutraceutical 26amp 3B 238220 3BInnovator 26amp 3B 238221 3B by Global Business Insights 14888 1WellGen Recognized as Nutraceutical 26amp 3B 238220 3BInnovator 26amp 3B 238221 3B by Global Business Insights 14888 2WellGen Recognized as Nutraceutical 26amp 3B 238220 3BInnovator 26amp 3B 238221 3B by Global Business Insights 14888 3Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 1Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 2Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 3Texas Laparoscopic Consultants Profiled on ABC 13 TV as the Only Practice in Houston Offering Single Incision Quick Recovery Weight Loss Surgery 61594 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |